Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab With or Without SRS in Recurrent or Advanced Chordoma
NCT02989636Phase 1Active, not recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Mar 2017
- Primary completion
- Apr 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab in chordoma (2 arms), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoint: Incidence of dose limiting toxicities at 12 weeks. Started Mar 2017; status: active, not recruiting.
02
Drugs
03
Conditions
chordoma
Beyond the preview
Go deeper on NCT02989636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02989636.